研究者業績

今井 靖

イマイ ヤスシ  (Yasushi Imai)

基本情報

所属
自治医科大学 医学部薬理学講座臨床薬理学部門 教授
医学部内科学講座循環器内科学部門 教授(兼)
学位
医学博士(東京大学)

J-GLOBAL ID
201401001007364738
researchmap会員ID
B000238134

外部リンク

論文

 168
  • Yasushi Imai, Kengo Kusano, Takeshi Aiba, Junya Ako, Yoshihiro Asano, Mariko Harada-Shiba, Masaharu Kataoka, Tomoki Kosho, Toru Kubo, Takayoshi Matsumura, Tetsuo Minamino, Kenji Minatoya, Hiroyuki Morita, Masakazu Nishigaki, Seitaro Nomura, Hitoshi Ogino, Seiko Ohno, Masayuki Takamura, Toshihiro Tanaka, Kenichi Tsujita, Tetsuro Uchida, Hiroyuki Yamagishi, Yusuke Ebana, Kanna Fujita, Kazufumi Ida, Shunsuke Inoue, Kaoru Ito, Yuki Kuramoto, Jun Maeda, Keiji Matsunaga, Reiko Neki, Kenta Sugiura, Hayato Tada, Akihiro Tsuji, Takanobu Yamada, Tomomi Yamaguchi, Eiichiro Yamamoto, Akinori Kimura, Koichiro Kuwahara, Koji Maemura, Tohru Minamino, Hiroko Morisaki, Katsushi Tokunaga
    Journal of cardiology 85(2) 115-176 2025年2月  
  • Yasuhiro Otsuka, Masanobu Ishii, So Ikebe, Taishi Nakamura, Kenichi Tsujita, Tetsuya Matoba, Takahide Kohro, Yusuke Oba, Tomoyuki Kabutoya, Kazuomi Kario, Yasushi Imai, Arihiro Kiyosue, Yoshiko Mizuno, Kotaro Nochioka, Masaharu Nakayama, Takamasa Iwai, Yoshihiro Miyamoto, Hisahiko Sato, Naoyuki Akashi, Hideo Fujita, Ryozo Nagai
    Open Heart 11(2) e002987-e002987 2024年12月23日  
    Background Hypertension is a risk factor for bleeding events and is included in the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/Alcohol concomitantly) score. However, the effects of blood pressure (BP) and changes in BP on bleeding events in patients undergoing percutaneous coronary intervention (PCI) remain poorly understood. This study is aimed to investigate the relationship between systolic BP (SBP) changes during hospitalisation and bleeding events in patients undergoing PCI. Methods From the Clinical Deep Data Accumulation System database, a multicentre database encompassing seven tertiary medical hospitals in Japan that includes data for patient characteristics, medications, laboratory tests, physiological tests, cardiac catheterisation and PCI treatment, data for 6351 patients undergoing PCI between April 2013 and March 2019 were obtained. The study population was categorised into three groups based on the changes in SBP during hospitalisation: (1) elevated BP (≥20 mm Hg), (2) no change (≥−20 to <20 mm Hg) and (3) decreased BP (<−20 mm Hg) groups. The primary outcome was a 3-year major bleeding event defined as moderate or severe bleeding according to the Global Use of Streptokinase and t-PA for Occluded Coronary Arteries bleeding criteria. Results The elevated BP group exhibited significantly lower SBP at admission and higher SBP at discharge (p<0.001). Multivariable Cox hazard regression models showed that elevated BP was associated with a high risk of bleeding events (HR: 1.885; 95% CI, 1.294 to 2.748). The multivariable logistic regression model identified female sex, chronic coronary syndrome, peripheral artery disease and chronic kidney disease as independent factors associated with elevated BP. Conclusions These findings suggest that BP management is essential to prevent bleeding events after PCI.
  • Yasuhiro Hitomi, Yasushi Imai, Masanari Kuwabara, Yusuke Oba, Tomoyuki Kabutoya, Kazuomi Kario, Hisaki Makimoto, Takahide Kohro, Eiichi Shiraki, Naoyuki Akashi, Hideo Fujita, Tetsuya Matoba, Yoshihiro Miyamoto, Arihiro Kiyosue, Kenichi Tsujita, Masaharu Nakayama, Ryozo Nagai
    IJC Heart & Vasculature 54 101507-101507 2024年10月  責任著者
    BACKGROUND: Polypharmacy is associated with an increased risk of adverse events due to the higher number of drugs used. This is particularly notable in patients with chronic coronary syndrome (CCS), who are known to use a large number of drugs. Therefore, we investigated polypharmacy in patients with CCS, using CLIDAS, a multicenter database of patients who underwent percutaneous coronary intervention. METHOD AND RESULTS: Between 2017 and 2020, 1411 CCS patients (71.5 ± 10.5 years old; 77.3 % male) were enrolled. The relationship between cardiovascular events occurring during the median follow-up of 514 days and the number of drugs at the time of PCI was investigated. The median number of drugs prescribed was nine. Major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, stroke, heart failure, transient ischemic attack, or unstable angina, occurred in 123 patients, and all-cause mortality occurred in 68 patients. For each additional drug, the adjusted hazard ratios for MACE and all-cause mortality increased by 2.069 (p = 0.003) and 1.102 (p = 0.010). The adjusted hazard ratios for MACE and all-cause mortality were significantly higher in the group using nine or more drugs compared to the group using eight or fewer drugs (1.646 and 2.253, both p < 0.001). CONCLUSION: This study showed that an increase in the number of drugs used for CCS may be associated with MACE and all-cause mortality. In patients with CCS, it might be beneficial to minimize the number of medications as much as possible, while managing comorbidities and using guideline-recommended drugs.
  • Yasushi Imai, Kengo Kusano, Takeshi Aiba, Junya Ako, Yoshihiro Asano, Mariko Harada-Shiba, Masaharu Kataoka, Tomoki Kosho, Toru Kubo, Takayoshi Matsumura, Tetsuo Minamino, Kenji Minatoya, Hiroyuki Morita, Masakazu Nishigaki, Seitaro Nomura, Hitoshi Ogino, Seiko Ohno, Masayuki Takamura, Toshihiro Tanaka, Kenichi Tsujita, Tetsuro Uchida, Hiroyuki Yamagishi, Yusuke Ebana, Kanna Fujita, Kazufumi Ida, Shunsuke Inoue, Kaoru Ito, Yuki Kuramoto, Jun Maeda, Keiji Matsunaga, Reiko Neki, Kenta Sugiura, Hayato Tada, Akihiro Tsuji, Takanobu Yamada, Tomomi Yamaguchi, Eiichiro Yamamoto, Akinori Kimura, Koichiro Kuwahara, Koji Maemura, Tohru Minamino, Hiroko Morisaki, Katsushi Tokunaga
    Circulation journal : official journal of the Japanese Circulation Society 88(12) 2022-2099 2024年9月27日  筆頭著者責任著者
  • Yusuke Oba, Tomoyuki Kabutoya, Takahide Kohro, Yasushi Imai, Kazuomi Kario, Hisahiko Sato, Kotaro Nochioka, Masaharu Nakayama, Naoyuki Akashi, Hideo Fujita, Yoshiko Mizuno, Arihiro Kiyosue, Takamasa Iwai, Yoshihiro Miyamoto, Yasuhiro Nakano, Masanobu Ishii, Taishi Nakamura, Kenichi Tsujita, Tetsuya Matoba, Ryozo Nagai
    Hypertension research : official journal of the Japanese Society of Hypertension 2024年9月19日  
    The Japanese Society of Hypertension have established a blood pressure (BP) target of 130/80 mmHg for patients with coronary artery disease (CAD). We evaluated the data of 8793 CAD patients in the Clinical Deep Data Accumulation System database who underwent cardiac catheterization at six university hospitals and the National Cerebral and Cardiovascular Center (average age 70 ± 11 years, 78% male, 43% with acute coronary syndrome [ACS]). Patients were divided into two groups based on whether or not they achieved the guideline-recommended BP of <130/80 mmHg. We analyzed the relationship between BP classification and major adverse cardiac and cerebral event (MACCE) separately in two groups: those with ACS and those with chronic coronary syndrome (CCS). During an average follow-up period of 33 months, 710 MACCEs occurred. A BP below 130/80 mmHg was associated with fewer MACCEs in both the overall (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.70-1.00, p = 0.048) and the ACS group (HR 0.67, 95%CI 0.51-0.88, p = 0.003). In particular, stroke events were also lower among those with a BP below 130/80 mmHg in both the overall (HR 0.69, 95%CI 0.53-0.90, p = 0.006) and ACS groups (HR 0.44, 95%CI 0.30-0.67, p < 0.001). In conclusion, the achievement of BP guidelines was associated with improved outcomes in CAD patients, particularly in reducing stroke risk among those with ACS.

MISC

 288

書籍等出版物

 13

共同研究・競争的資金等の研究課題

 13